- Home
- SAGE vs JMIA Comparison
SAGE vs JMIA Comparison
Compare SAGE & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- JMIA
- Stock Information
- Founded
- SAGE 2010
- JMIA 2012
- Country
- SAGE United States
- JMIA Germany
- Employees
- SAGE N/A
- JMIA N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- JMIA Catalog/Specialty Distribution
- Sector
- SAGE Health Care
- JMIA Consumer Discretionary
- Exchange
- SAGE Nasdaq
- JMIA Nasdaq
- Market Cap
- SAGE 444.1M
- JMIA 475.2M
- IPO Year
- SAGE 2014
- JMIA 2019
- Fundamental
- Price
- SAGE $7.50
- JMIA $2.42
- Analyst Decision
- SAGE Hold
- JMIA Buy
- Analyst Count
- SAGE 20
- JMIA 2
- Target Price
- SAGE $10.56
- JMIA $7.88
- AVG Volume (30 Days)
- SAGE 1.6M
- JMIA 4.6M
- Earning Date
- SAGE 04-24-2025
- JMIA 02-20-2025
- Dividend Yield
- SAGE N/A
- JMIA N/A
- EPS Growth
- SAGE N/A
- JMIA N/A
- EPS
- SAGE N/A
- JMIA N/A
- Revenue
- SAGE $41,243,000.00
- JMIA $167,486,000.00
- Revenue This Year
- SAGE $105.47
- JMIA $20.80
- Revenue Next Year
- SAGE $67.53
- JMIA $6.63
- P/E Ratio
- SAGE N/A
- JMIA N/A
- Revenue Growth
- SAGE N/A
- JMIA N/A
- 52 Week Low
- SAGE $4.62
- JMIA $2.21
- 52 Week High
- SAGE $22.18
- JMIA $15.04
- Technical
- Relative Strength Index (RSI)
- SAGE 60.15
- JMIA 30.54
- Support Level
- SAGE $7.07
- JMIA $2.21
- Resistance Level
- SAGE $7.64
- JMIA $2.56
- Average True Range (ATR)
- SAGE 0.27
- JMIA 0.21
- MACD
- SAGE 0.00
- JMIA -0.05
- Stochastic Oscillator
- SAGE 78.74
- JMIA 10.05
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.